Randomized trial of low-intensity vibration for chemotherapy-induced peripheral neuropathy in cancer survivors

Vibration therapy shows promise as intervention for chemotherapy-induced peripheral neuropathy (CIPN) but is understudied. A randomized trial at Oregon Health & Science University (Portland) evaluated low-intensity vibration (LIV) versus usual care (UC) in cancer survivors with persistent CIPN symptoms. There were no serious adverse events. Trial retention was 97% and mean adherence to LIV was 77 ± 18%. Compared with UC, LIV participants reported greater improvements in sensory neuropathy symptoms and basic lower extremity function, with moderate-to-large effect sizes for changes in stability, mobility, and gait. The authors conclude that LIV was safe and feasible and showed preliminary efficacy for CIPN symptom relief and improving physical functioning in cancer survivors with CIPN.